Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Non-Current Assets (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Non-Current Assets for 16 consecutive years, with $719000.0 as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 297.24% to $719000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $719000.0 through Dec 2025, up 297.24% year-over-year, with the annual reading at $719000.0 for FY2025, 297.24% up from the prior year.
  • Non-Current Assets hit $719000.0 in Q4 2025 for Guided Therapeutics, up from $104000.0 in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $719000.0 in Q4 2025 to a low of $104000.0 in Q3 2025.
  • Historically, Non-Current Assets has averaged $322450.0 across 5 years, with a median of $330500.0 in 2023.
  • Biggest five-year swings in Non-Current Assets: surged 570.97% in 2021 and later plummeted 49.51% in 2025.
  • Year by year, Non-Current Assets stood at $403000.0 in 2021, then dropped by 10.17% to $362000.0 in 2022, then fell by 23.76% to $276000.0 in 2023, then tumbled by 34.42% to $181000.0 in 2024, then surged by 297.24% to $719000.0 in 2025.
  • Business Quant data shows Non-Current Assets for GTHP at $719000.0 in Q4 2025, $104000.0 in Q3 2025, and $129000.0 in Q2 2025.